VG161

AXP000082.1 · Oncolytic virus

Platform
HSV-1 (ICP34.5- ICP47-)
Originator
Virogin Biotech
Sponsor
CNBG-Virogin Biotech (Shanghai)

Names

NameTypeSource
VG161preferred name, codecurator, ncit
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)synonymctgov

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
ICP34.5 and ICP47 deleted
Transgenes
IL12A, IL12B, IL15, IL15RA, PD-L1 blocking peptide
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C179675

Approvals

No regulatory approval recorded.

Clinical trials (9)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05223816An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaUnknownPhase 22024-01-242025-10-0197Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
NCT06124001Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular CarcinomaUnknownPhase 1/22023-11-302025-12-3036Primary Hepatocellular Carcinoma
NCT06126510Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue SarcomaRecruitingPhase 22023-07-182025-07-1740Sarcoma
NCT06008925Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerUnknownPhase 1/22022-11-172025-1243Metastatic Gastric Cancer
NCT06746480Clinical Study of VG161 in Advanced Intrahepatic CholangiocarcinomaRecruitingPhase 22022-03-192025-09-3033Advanced Intrahepatic Cholangiocarcinoma
NCT05162118Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerUnknownPhase 1/22022-03-082025-03-2251Advanced Pancreatic Cancer
NCT07505615A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerCompletedPhase 1/22021-10-122023-04-2820NMIBC
NCT04758897Clinical Study of VG161 in Subjects With Advanced Malignant Solid TumorsUnknownPhase 12021-04-142022-03-1418Advanced Malignant Solid Tumor
NCT04806464Clinical Study of VG161 in Subjects with Advanced Primary Liver CancerUnknownPhase 12021-03-162022-03-2144Primary Liver Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40108464Oncolytic virus VG161 in refractory hepatocellular carcinoma.Nature2025cited by trial NCT04806464
PMID 38638849Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases.Oncology letters2024name in abstract: VG161

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42362102VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity.Cancer letters2026name in title: VG161
PMID 42371785Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026name in title: VG161
PMID 42909267Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.Frontiers in cell and developmental biology2026name in abstract: VG161
PMID 40269171Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinoma.Nature2025name in title: VG161
PMID 40718827Oncolytic virus VG161 offers new hope for refractory liver cancer.Frontiers in oncology2025name in title: VG161
PMID 41022576Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.Gut2025name in title: VG161
PMID 41231105Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy.Advances in clinical and experimental medicine : official organ Wroclaw Medical University2025name in abstract: VG161
PMID 36042555VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes.Journal of medical virology2023name in title: VG161
PMID 37212336Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.Journal of medical virology2023name in abstract: VG161
PMID 36366425Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.Viruses2022name in abstract: VG161
PMID 33182232Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes.Biomedicines2020name in abstract: VG161

Notes

Registered in China as 'recombinant human IL12/IL15-PDL1B oncolytic HSV-1 injection (Vero cell)'. Trials in hepatocellular carcinoma, cholangiocarcinoma, pancreatic and gastric cancer.

How to cite

VG161 (AXP000082.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000082.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.